It's a thought we've all had: Why limit yourself to investing domestically if to do so means missing out on lucrative skyrocketing international stocks (Tesla, say, or Tencent, or Apple in 2020).

Thankfully there is an answer. Time and time again the Australian market has been one of the highest returning markets in the world over the long term.

Australian companies have been able to compete on the global stage in a number of themes: Healthcare (darlings like CSL, Fisher and Paykel and Resmed) and Tech (Xero, Afterpay and Zip) to name but two. 

And Randal Jenneke head of the Australian equities at T. Rowe Price thinks the recent market rotation from Growth to Value could present a chance to capitalise on overselling of the latter and sees opportunities domestically. 

Accordingly, Jenneke discusses the strength of the Australian market, opportunities arising from a market rotation and how our Aussie faves can fend off the copy cats.